SI2293795T1 - Farmacevtska kombinacija - Google Patents
Farmacevtska kombinacijaInfo
- Publication number
- SI2293795T1 SI2293795T1 SI200931315T SI200931315T SI2293795T1 SI 2293795 T1 SI2293795 T1 SI 2293795T1 SI 200931315 T SI200931315 T SI 200931315T SI 200931315 T SI200931315 T SI 200931315T SI 2293795 T1 SI2293795 T1 SI 2293795T1
- Authority
- SI
- Slovenia
- Prior art keywords
- pharmaceutical combination
- pharmaceutical
- combination
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08157749 | 2008-06-06 | ||
US7888208P | 2008-07-08 | 2008-07-08 | |
PCT/EP2009/056891 WO2009147218A1 (en) | 2008-06-06 | 2009-06-04 | Pharmaceutical combination |
EP09757599.7A EP2293795B1 (en) | 2008-06-06 | 2009-06-04 | Pharmaceutical combination |
Publications (1)
Publication Number | Publication Date |
---|---|
SI2293795T1 true SI2293795T1 (sl) | 2015-12-31 |
Family
ID=40912046
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI200931819T SI2985025T1 (sl) | 2008-06-06 | 2009-06-04 | Farmacevtska kombinacija |
SI200931315T SI2293795T1 (sl) | 2008-06-06 | 2009-06-04 | Farmacevtska kombinacija |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI200931819T SI2985025T1 (sl) | 2008-06-06 | 2009-06-04 | Farmacevtska kombinacija |
Country Status (34)
Country | Link |
---|---|
US (5) | US20110178099A1 (sl) |
EP (2) | EP2293795B1 (sl) |
JP (2) | JP5993573B2 (sl) |
KR (1) | KR101760657B1 (sl) |
CN (1) | CN102056609B (sl) |
AR (1) | AR072061A1 (sl) |
AU (1) | AU2009254554B2 (sl) |
CA (1) | CA2726644C (sl) |
CO (1) | CO6280488A2 (sl) |
CY (2) | CY1116877T1 (sl) |
DK (2) | DK2293795T3 (sl) |
EA (1) | EA020046B1 (sl) |
EC (1) | ECSP10010716A (sl) |
ES (2) | ES2662824T3 (sl) |
HK (1) | HK1152640A1 (sl) |
HR (2) | HRP20151186T1 (sl) |
HU (2) | HUE037291T2 (sl) |
IL (1) | IL208953B (sl) |
LT (1) | LT2985025T (sl) |
MA (1) | MA32384B1 (sl) |
ME (1) | ME02273B (sl) |
MX (1) | MX338047B (sl) |
MY (1) | MY158929A (sl) |
NZ (1) | NZ588957A (sl) |
PE (1) | PE20100084A1 (sl) |
PL (2) | PL2985025T3 (sl) |
PT (2) | PT2985025T (sl) |
RS (2) | RS54293B1 (sl) |
SI (2) | SI2985025T1 (sl) |
TW (1) | TWI447113B (sl) |
UA (1) | UA102258C2 (sl) |
UY (1) | UY31866A (sl) |
WO (1) | WO2009147218A1 (sl) |
ZA (1) | ZA201007594B (sl) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050043233A1 (en) | 2003-04-29 | 2005-02-24 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis |
PE20060777A1 (es) | 2004-12-24 | 2006-10-06 | Boehringer Ingelheim Int | Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas |
EA029996B1 (ru) * | 2008-06-06 | 2018-06-29 | ĐŃŃĐžĐœĐłĐ”Ń ĐĐœĐłĐ”Đ»ŃŃ Đ°ĐčĐŒ ĐĐœŃĐ”ŃĐœĐ°ŃĐžĐŸĐœĐ°Đ»Ń ĐĐŒĐ±Ń | ĐĐ°ĐżŃŃĐ»ŃŃĐœĐ°Ń Đ»Đ”ĐșĐ°ŃŃŃĐČĐ”ĐœĐœĐ°Ń ŃĐŸŃĐŒĐ°, ŃĐŸĐŽĐ”ŃжаŃĐ°Ń ŃŃŃĐżĐ”ĐœĐ·ĐžĐŸĐœĐœŃŃ ĐșĐŸĐŒĐżĐŸĐ·ĐžŃĐžŃ ĐżŃĐŸĐžĐ·ĐČĐŸĐŽĐœĐŸĐłĐŸ ĐžĐœĐŽĐŸĐ»ĐžĐœĐŸĐœĐ° |
US20170065529A1 (en) | 2015-09-09 | 2017-03-09 | Boehringer Ingelheim International Gmbh | Pharmaceutical dosage form for immediate release of an indolinone derivative |
UA107560C2 (uk) * | 2008-06-06 | 2015-01-26 | ЀаŃĐŒĐ°ŃĐ”ĐČŃĐžŃĐœĐ° Đ»ŃĐșĐ°ŃŃŃĐșĐ° ŃĐŸŃĐŒĐ° ĐŽĐ»Ń ĐœĐ”ĐłĐ°ĐčĐœĐŸĐłĐŸ ĐČĐžĐČŃĐ»ŃĐœĐ”ĐœĐœŃ ĐżĐŸŃ ŃĐŽĐœĐŸŃ ŃĐœĐŽĐŸĐ»ŃĐœĐŸĐœŃ | |
US20140350022A1 (en) * | 2013-05-10 | 2014-11-27 | Boehringer Ingelheim International Gmbh | Efficacious treatment of NSCLC and predictive clinical marker of the responsiveness of a tumour to a treatment |
ES2775179T3 (es) * | 2015-10-21 | 2020-07-24 | Capsugel Belgium Nv | Proceso de impresiĂłn para formas de dosificaciĂłn orales |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL96531A (en) | 1989-12-11 | 1995-08-31 | Univ Princeton | History of Acid N- (Diomeric-H1-Pyrolo] D-2,3 [Pyrimidine-3-Ilacyl (-glutamic, preparation and pharmaceutical preparations containing them) |
AU6890800A (en) * | 1999-08-23 | 2001-03-19 | Eli Lilly And Company | A novel crystalline form of disodium n-[4-[2-(2-amino-4,7-dihydro-4-oxo-3h-pyrrolo[2,3-D]- pyrimidin-5-yl)ethyl]benzoyl]-l-glutamic acid salt and processes therefor |
UA75054C2 (uk) | 1999-10-13 | 2006-03-15 | ĐŃĐŸŃŃĐœĐłĐ”Ń ĐĐœĐłĐ”Đ»ŃŃ Đ°ĐčĐŒ ЀаŃĐŒĐ° ĐĐŒĐ±Ń & ĐĐŸ. ĐĐł | ĐĐ°ĐŒŃŃĐ”ĐœŃ ĐČ ĐżĐŸĐ»ĐŸĐ¶Đ”ĐœĐœŃ 6 ŃĐœĐŽĐŸĐ»ŃĐœĐŸĐœĐž, ŃŃ ĐŸĐŽĐ”ŃĐ¶Đ°ĐœĐœŃ ŃĐ° ŃŃ Đ·Đ°ŃŃĐŸŃŃĐČĐ°ĐœĐœŃ ŃĐș Đ»ŃĐșĐ°ŃŃŃĐșĐŸĐłĐŸ Đ·Đ°ŃĐŸĐ±Ń |
DE10233500A1 (de) | 2002-07-24 | 2004-02-19 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylen]-6-methoxycarbonyl-2-indolinon-Monoethansulfonat und dessen Verwendung als Arzneimittel |
US20040204458A1 (en) * | 2002-08-16 | 2004-10-14 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Use of Lck inhibitors for treatment of immunologic diseases |
DE10237423A1 (de) | 2002-08-16 | 2004-02-19 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verwendung von LCK-Inhibitoren fĂŒr die Behandlung von immunologischen Erkrankungen |
US7148249B2 (en) * | 2002-09-12 | 2006-12-12 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments |
US20050043233A1 (en) * | 2003-04-29 | 2005-02-24 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis |
EP1711209A4 (en) * | 2004-01-23 | 2007-09-26 | Sarissa Inc | METHOD FOR TREATING MESOTHELION WITH AN ANTISENSE OLIGONUCLEOTIDE AGAINST TYHMIDYLATE SYNTHASE |
US20060058311A1 (en) * | 2004-08-14 | 2006-03-16 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation |
US20060041013A1 (en) * | 2004-08-18 | 2006-02-23 | Brittain Jason E | Alanosine formulations and methods of use |
PE20060777A1 (es) * | 2004-12-24 | 2006-10-06 | Boehringer Ingelheim Int | Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas |
WO2007057397A1 (en) * | 2005-11-15 | 2007-05-24 | Boehringer Ingelheim International Gmbh | Treatment of cancer |
EP1870400A1 (en) | 2006-06-08 | 2007-12-26 | Boehringer Ingelheim Pharma GmbH & Co. KG | Salts and crystalline salt forms of an 2-indolinone derivative |
EP1934226A2 (en) * | 2006-08-14 | 2008-06-25 | Sicor, Inc. | Highly pure pemetrexed diacid and processes for the preparation thereof |
-
2009
- 2009-06-04 HU HUE15179438A patent/HUE037291T2/hu unknown
- 2009-06-04 CA CA2726644A patent/CA2726644C/en not_active Expired - Fee Related
- 2009-06-04 PT PT151794385T patent/PT2985025T/pt unknown
- 2009-06-04 DK DK09757599.7T patent/DK2293795T3/en active
- 2009-06-04 ME MEP-2015-165A patent/ME02273B/me unknown
- 2009-06-04 EP EP09757599.7A patent/EP2293795B1/en active Active
- 2009-06-04 AU AU2009254554A patent/AU2009254554B2/en not_active Ceased
- 2009-06-04 EA EA201001853A patent/EA020046B1/ru not_active IP Right Cessation
- 2009-06-04 PE PE2009000779A patent/PE20100084A1/es not_active Application Discontinuation
- 2009-06-04 PL PL15179438T patent/PL2985025T3/pl unknown
- 2009-06-04 US US12/995,882 patent/US20110178099A1/en not_active Abandoned
- 2009-06-04 DK DK15179438.5T patent/DK2985025T3/en active
- 2009-06-04 WO PCT/EP2009/056891 patent/WO2009147218A1/en active Application Filing
- 2009-06-04 UA UAA201100102A patent/UA102258C2/ru unknown
- 2009-06-04 SI SI200931819T patent/SI2985025T1/sl unknown
- 2009-06-04 HU HUE09757599A patent/HUE025821T2/en unknown
- 2009-06-04 EP EP15179438.5A patent/EP2985025B1/en active Active
- 2009-06-04 ES ES15179438.5T patent/ES2662824T3/es active Active
- 2009-06-04 UY UY0001031866A patent/UY31866A/es not_active Application Discontinuation
- 2009-06-04 RS RS20150690A patent/RS54293B1/en unknown
- 2009-06-04 JP JP2011512132A patent/JP5993573B2/ja not_active Expired - Fee Related
- 2009-06-04 PL PL09757599T patent/PL2293795T3/pl unknown
- 2009-06-04 MY MYPI2010005701A patent/MY158929A/en unknown
- 2009-06-04 SI SI200931315T patent/SI2293795T1/sl unknown
- 2009-06-04 PT PT97575997T patent/PT2293795E/pt unknown
- 2009-06-04 LT LTEP15179438.5T patent/LT2985025T/lt unknown
- 2009-06-04 KR KR1020107027337A patent/KR101760657B1/ko active IP Right Grant
- 2009-06-04 MX MX2010012937A patent/MX338047B/es active IP Right Grant
- 2009-06-04 CN CN2009801211276A patent/CN102056609B/zh not_active Expired - Fee Related
- 2009-06-04 NZ NZ588957A patent/NZ588957A/xx not_active IP Right Cessation
- 2009-06-04 RS RS20180319A patent/RS57035B1/sr unknown
- 2009-06-04 ES ES09757599.7T patent/ES2552238T3/es active Active
- 2009-06-05 AR ARP090102041A patent/AR072061A1/es unknown
- 2009-06-05 TW TW098118817A patent/TWI447113B/zh not_active IP Right Cessation
-
2010
- 2010-10-25 ZA ZA2010/07594A patent/ZA201007594B/en unknown
- 2010-10-26 IL IL208953A patent/IL208953B/en active IP Right Grant
- 2010-12-03 CO CO10152525A patent/CO6280488A2/es not_active Application Discontinuation
- 2010-12-06 MA MA33401A patent/MA32384B1/fr unknown
- 2010-12-23 EC EC2010010716A patent/ECSP10010716A/es unknown
-
2011
- 2011-06-24 HK HK11106535.6A patent/HK1152640A1/xx not_active IP Right Cessation
-
2013
- 2013-04-24 US US13/869,139 patent/US20130237549A1/en not_active Abandoned
-
2014
- 2014-10-16 JP JP2014211603A patent/JP2015007143A/ja not_active Withdrawn
-
2015
- 2015-03-05 US US14/639,265 patent/US20150174126A1/en not_active Abandoned
- 2015-11-03 CY CY20151100977T patent/CY1116877T1/el unknown
- 2015-11-05 HR HRP20151186TT patent/HRP20151186T1/hr unknown
-
2016
- 2016-05-06 US US15/147,929 patent/US20160250218A1/en not_active Abandoned
-
2018
- 2018-04-16 HR HRP20180602TT patent/HRP20180602T1/hr unknown
- 2018-04-17 CY CY20181100403T patent/CY1120505T1/el unknown
- 2018-05-01 US US15/967,607 patent/US20180243308A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL237392A0 (en) | Pharmaceutical combination | |
ZA201104336B (en) | Pharmaceutical compounds | |
GB0816372D0 (en) | Pharmaceutical compounds | |
GB0820819D0 (en) | Pharmaceutical compounds | |
GB0801416D0 (en) | Pharmaceutical compounds | |
IL207378A0 (en) | Pharmaceutical solid state forms | |
GB0816371D0 (en) | Pharmaceutical compounds | |
GB0810615D0 (en) | Novel pharmaceutical | |
ZA201104348B (en) | Pharmaceutical preparation | |
GB0812969D0 (en) | Pharmaceutical compounds | |
PT2271618E (pt) | Compostos farmacĂȘuticos | |
GB0816370D0 (en) | Pharmaceutical compounds | |
HUP0800591A2 (en) | Stable pharmaceutical combination | |
GB0815972D0 (en) | Pharmaceutical preparation | |
HK1152640A1 (en) | Pharmaceutical combination | |
GB0810857D0 (en) | Pharmaceutical compounds | |
EP2268278A4 (en) | PHARMACEUTICAL COMPOSITION | |
GB0803054D0 (en) | Medicament | |
GB0810617D0 (en) | Novel pharmaceutical | |
GB0817969D0 (en) | Pharmaceutical composition | |
HU0800414D0 (en) | Pharmaceutical combination | |
GB0804486D0 (en) | Novel pharmaceutical composituons | |
GB0803395D0 (en) | Medicament | |
GB0817006D0 (en) | Pharmaceutical compounds | |
GB0807502D0 (en) | Pharmaceutical compounds |